Abstract
A case of a patient presenting with idiopathic concurrent erythrocytic and megakaryocytic aplasia is reported. The patient's response to immunosuppressive therapy and her bone marrow pathology clearly suggest an immune mechanism. Based on the lack of suppression of erythroid colony growth, several mechanisms are postulated. Well-established molecular and genetic evidence, along with clinical observations, suggests that a relationship exists between the erythrocytic and megakaryocytic cell lines. This may be related to a common bipotential stem cell or common cell surface markers. This case provides strong clinical evidence to support this relationship.
MeSH terms
-
Adult
-
Antibodies, Viral / analysis
-
Autoimmune Diseases / pathology
-
Bone Marrow / pathology*
-
Cell Lineage
-
Cyclophosphamide / therapeutic use
-
Cyclosporine / therapeutic use
-
Erythroid Precursor Cells / pathology*
-
Female
-
Hematopoiesis
-
Hepatitis B Surface Antigens / analysis
-
Hepatitis C Antibodies / analysis
-
Humans
-
Immunity, Cellular
-
Immunoglobulin G / analysis
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Megakaryocytes / pathology*
-
Parvovirus B19, Human / immunology
-
Platelet Transfusion
-
Prednisone / therapeutic use
-
Red-Cell Aplasia, Pure / complications*
-
Red-Cell Aplasia, Pure / immunology
-
Red-Cell Aplasia, Pure / therapy
-
Thrombocytopenia / complications*
-
Thrombocytopenia / immunology
-
Thrombocytopenia / therapy
-
Vincristine / therapeutic use
Substances
-
Antibodies, Viral
-
Hepatitis B Surface Antigens
-
Hepatitis C Antibodies
-
Immunoglobulin G
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Vincristine
-
Cyclosporine
-
Cyclophosphamide
-
Prednisone